Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement
August 21, 2023 14:37 ET
|
Psyence Group Inc.
TORONTO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement
August 02, 2023 10:34 ET
|
Psyence Group Inc.
VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural...
Psyence Group Corporate Update
July 12, 2023 07:00 ET
|
Psyence Group Inc.
Highlights: Drug development, Phase IIb clinical trial advanced planning underway in AustraliaPsyence granted worldwide licensing agreement to commercialize Filament’s PEX010 (25 mg) in...
Psyence Appoints Intellectual Property Expert to Its Board of Directors
July 11, 2023 07:00 ET
|
Psyence Group Inc.
TORONTO, July 11, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce the appointment of Christopher Bull to the board of...
Psyence Group Announces Closing of Fourth Tranche of Private Placement and Conversion of Convertible Debt Note
April 03, 2023 14:44 ET
|
Psyence Group Inc.
TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Psyence Group inc. (CSE:PSYG | OTCQB:PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics...
Psyence Group Announces Cantheon Capital Private Placement
March 23, 2023 07:00 ET
|
Psyence Group Inc.
VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental...
Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia
March 21, 2023 07:00 ET
|
Psyence Group Inc.
VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental...
Psyence and Eden Labs Announce Extraction and Product Development Collaboration
January 24, 2023 07:00 ET
|
Psyence Group Inc.
TORONTO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG. |. OTCQB: PSYGF) (Psyence or the Company), a life science biotechnology company pioneering the use of natural psychedelics...
Psyence Group Completes Export of Pharma Grade Psilocybin Extract to UK
January 20, 2023 07:00 ET
|
Psyence Group Inc.
TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that it has exported purified pharmaceutical grade...
Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp
January 09, 2023 17:47 ET
|
Psyence Group Inc.
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental...